Skip to main content
SpringerLink
Log in

Pharmacokinetics of Antibiotics During Continuous Renal Replacement Therapy

  • Conference paper
Yearbook of Intensive Care and Emergency Medicine 2005

Part of the book series: EN]Yearbook of Intensive Care and Emergency Medicine ((volume 2005))

  • 645 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Schroeder TH, Hansen M, Dinkelacker K, et al (2005) Influence of underlying disease on the outcome of critically ill patients with acute renal failure Eur J Anaesthesiol 21 (in press)

    Google Scholar 

  2. Ronco C, Bellomo R, Homel P, et al (2000) Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. Lancet 356:26–30

    Article  PubMed  Google Scholar 

  3. Cotterill S (1995) Antimicrobial prescribing in patients on haemofiltration. J Antimicrob Chemother 36:773–780

    PubMed  Google Scholar 

  4. Olbricht CJ (1992) Pharmakotherapie bei kontinuierlicher Hämofiltration CAVH/CVVH. Intensivmed 29:4–8

    Google Scholar 

  5. Fuhrmann V, Schenk P, Jaeger W, Ahmed S, Thalhammer F (2004) Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration J Antimicrob Chemother 54:780–784

    Article  PubMed  Google Scholar 

  6. Davies JG, Kingswood JC, Sharpstone P, Street MK (1995) Drug removal in continuous haemofiltration and haemodialysis. Br J Hosp Med 54:524–528

    PubMed  Google Scholar 

  7. Reetze-Bonorden P, Böhler J, Keller E (1993) Drug dosage in patients during continuous renal replacement therapy. Clin Pharmacokinet 24:362–379

    PubMed  Google Scholar 

  8. Golper TA (1985) Continuous arteriovenous hemofiltration in acute renal failure. Am J Kidney Dis 6:373–386

    PubMed  Google Scholar 

  9. Schroeder TH, Krueger WA, Hansen M, Hoffmann E, Dieterich HJ, Unertl K (1999) Elimination of meropenem by continuous hemo(dia)filtration: an in vitro one-compartment model. Int J Artif Organs 22:307–312

    PubMed  Google Scholar 

  10. Sörgel F, Kinzig M, Naber KG (1993) Macrolides. In: Bryskier A, Butzler JP, Neu HC (eds) Chemistry, Pharmacology and Clinical Uses. Arnette Blackwell, Paris, France, pp 421–435

    Google Scholar 

  11. Lugo G, Castañeda-Hernández G (1997) Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 25:806–811

    PubMed  Google Scholar 

  12. Niemiec PW, Allo MD, Miller CF (1987) Effect of altered volume of distribution on amino-glycoside levels in patients in surgical intensive care. Arch Surg 122:207–212

    PubMed  Google Scholar 

  13. van Dalen R, Vree TB (1990) Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med 16:235–238

    Article  Google Scholar 

  14. Sörgel F, Kinzig M (1993) Pharmacokinetics of gyrase inhibitors, part 1: basic chemistry and gastrointestinal disposition. Am J Med 94(Suppl 3A):44S–55S

    PubMed  Google Scholar 

  15. Birnbaum J, Kahan FM, Kropp H, McDonald JS (1985) Carbapenems, a new class of antibiotics. Discovery and development of imipenem/cilastatin. Am J Med 78(Suppl 6A):3–21

    Article  Google Scholar 

  16. Keller E, Fecht H, Böhler J, Schollmeyer P (1989) Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients. Nephrol Dial Transplant 4:640–645

    PubMed  Google Scholar 

  17. Przechera M, Bengel D, Risler T (1991) Pharmacokinetics of imipenem/cilastatin during continuous arteriovenous hemofiltration. Contrib Nephrol 93:131–134

    PubMed  Google Scholar 

  18. Tegeder I, Bremer F, Oelkers R, et al (1997) Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother 41:2640–2645

    PubMed  Google Scholar 

  19. Vos MC, Vincent HH, Yzerman EPF (1992) Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD). Intensive Care Med 18:282–285

    PubMed  Google Scholar 

  20. Alarabi AA, Cars O, Danielson BG, Salmonson T, Wikström B (1990) Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration. J Antimicrob Chemother 26:91–98

    Google Scholar 

  21. Mueller BA, Scarim SK, Macias WL (1993) Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am J Kidney Dis 21:172–179

    PubMed  Google Scholar 

  22. Hashimoto S, Honda M, Yamaguchi M, Sekimoto M, Tanaka Y (1997) Pharmacokinetics of imipenem and cilastatin during continuous hemodialysis in patients who are critically ill. ASAIO J 43:84–88

    PubMed  Google Scholar 

  23. Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ (1989) The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 24(Suppl A):311–320

    Google Scholar 

  24. Fukasawa M, Sumita Y, Harabe ET, et al (1992) Stability of meropenem and the effect of 1-β-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob Agents Chemother 36:1577–1579

    PubMed  Google Scholar 

  25. Tegeder I, Neumann F, Bremer F, Brune K, Lötsch J, Geisslinger G (1999) Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous veno-venous hemofiltration. Clin Pharmacol Ther 65:50–57

    PubMed  Google Scholar 

  26. Craig WA (1995) Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad spectrum cephalosporins. Diag Microbiol Infect Dis 22:89–96

    Article  Google Scholar 

  27. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA (1988) Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 158:831–847

    PubMed  Google Scholar 

  28. Bustamante CI, Drusano GL, Tatem BA, Standiford HC (1984) Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother 26:678–682

    PubMed  Google Scholar 

  29. Munckhof WJ, Olden D, Turnidge JD (1997) The postantibiotic effect of imipenem: relationship with drug concentration, duration of exposure, and MIC. Antimicrob Agents Chemother 41:1735–1737

    PubMed  Google Scholar 

  30. Nadler HL, Pitkin DH, Sheikh W (1989) The postantibiotic effect of meropenem and imipenem on selected bacteria. J Antimicrob Chemother 24(Suppl A):225–231

    PubMed  Google Scholar 

  31. Drusano GL, Hutchison M (1995) The pharmacokinetics of meropenem. Scand J Infect Dis Suppl 96:11–16

    Google Scholar 

  32. National Committee for Clinical Laboratory Standards (1998) Performance standards for antimicrobial susceptibility testing. Eighth informational supplement. NCCLS, Wayne 18:12

    Google Scholar 

  33. Krueger WA, Schroeder TH, Hutchison M, et al (1998) Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 42:2421–2424

    PubMed  Google Scholar 

  34. Krueger WA, Neeser G, Schuster H, et al (2003) Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration. Chemother 49:280–286

    Article  Google Scholar 

  35. Capellier G, Cornette C, Boillot A, et al (1998) Removal of piperacillin in critically ill patients undergoing venovenous hemofiltration. Crit Care Med 26:88–91

    PubMed  Google Scholar 

  36. van der Werf TS, Mulder POM, Zijlstra JG, Uges DRA, Stegeman CA (1997) Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 23:873–877

    Article  PubMed  Google Scholar 

  37. Valtonen M, Tiula E, Takkunen O, Backman JT, Neuvonen PJ (2001) Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 48:881–885

    Article  PubMed  Google Scholar 

  38. Krueger WA, Ruckdeschel G, Unertl K (1997) Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate. Antimicrob Agents Chemother 41:1725–17230

    PubMed  Google Scholar 

  39. Krueger WA, Ruckdeschel G, Unertl K (1999) Elimination of fecal Enterobacteriaceae by intravenous ciprofloxacin is not inhibited by concomitant sucralfate — a microbiological and pharmacokinetic study in patients. Infection 27:335–340

    Article  PubMed  Google Scholar 

  40. Rohwedder RW, Bergan T, Thorsteinsson SB, Scholl H (1990) Transintestinal elimination of ciprofloxacin. Diag Microbiol Infect Dis 13:127–133

    Article  Google Scholar 

  41. Malone RS, Fish DN, Abraham E, Teitelbaum I (2001) Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 45:2949–2954

    Article  PubMed  Google Scholar 

  42. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing in mice and men. Clin Infect Dis 26:1–12

    PubMed  Google Scholar 

  43. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS (1999) Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria. Antimicrob Agents Chemother 43:623–629

    PubMed  Google Scholar 

  44. Moore RD, Smith CR, Lietman PS (1984) Association of aminoglycoside plasma levels with therapeutic outcome in Gram-negative pneumonia. Am J Med 77:657–662

    Article  PubMed  Google Scholar 

  45. Beaucaire C (2000) Does once-daily dosing prevent nephrotoxicity in all aminoglycosides equally? Clin Microbiol Infect 6:357–362

    Article  PubMed  Google Scholar 

  46. Hatala R, Dinh T, Cook DJ (1996) Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 124:717–725

    PubMed  Google Scholar 

  47. Cigarran-Guldris S, Brier ME, Golper TA (1991) Tobramycin clearance during simulated continuous arteriovenous hemodialysis. Contrib Nephrol 93:120–123

    PubMed  Google Scholar 

  48. Kronfol NO, Lau AH, Barakat MM (1987) Aminoglycoside binding to polyacrylonitril hemofilter membranes during continuous hemofiltration. Trans Am Soc Artif Intern Organs 33:300–303

    Google Scholar 

  49. Böhler J, Reetze-Bonorden P, Keller E, Kramer A, Schollmeyer PJ (1992) Rebound of plasma vancomycin levels after haemodialysis with highly permeable membranes. Eur J Clin Pharmacol 42:635–640

    PubMed  Google Scholar 

  50. Boereboom FTJ, Ververs FFT, Blankestijn PJ, Savelkoul TJF, van Dijk A (1999) Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Intensive Care Med 25:1100–1104

    Article  PubMed  Google Scholar 

  51. Foote EF, Dreitlein WB, Steward CA, Kapoian T, Walker JA, Sherman RA (1998) Pharmacokinetics of vancomycin when administered during high flux hemodialysis Clin Nephrol 50:51–55

    PubMed  Google Scholar 

  52. Uchino S, Cole L, Morimatsu H, Goldsmith D, Bellomo R (2002) Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution. Intensive Care Med 28:1664–1667

    Article  PubMed  Google Scholar 

  53. Krueger WA, Unertl KE (2002) Neue Therapieoption für Intensivpatienten mit Infektionen durch Gram-positive Bakterien — Überblick über Linezolid. Anästhesiol Intensivmed Not-fallmed Schmerzther 37:199–204

    Article  Google Scholar 

  54. Schroeder TH, Kansen M, Stephan M, Hoffmann E, Unertl K, Krueger WA (2004) Elimination of linezolid by an in vitro extracorporeal circuit model. Int J Artif Org 27:473–479

    Google Scholar 

  55. Brier ME, Stalker DJ, Aronow DR, Batts DH, Ryan KK, O'Grady NP, Hopkins NK, Jungblut GL (2003) Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 47:2775–2780

    Article  PubMed  Google Scholar 

Download references

Authors
  1. W.A. Krueger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T.H. Schroeder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Intensive Care Erasme Hospital, Free University of Brussels, Route de Lennik 808, B-1070, Brussels, Belgium

    Jean-Louis Vincent (Head) (Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Krueger, W., Schroeder, T., Hansen, M. (2005). Pharmacokinetics of Antibiotics During Continuous Renal Replacement Therapy. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine 2005. EN]Yearbook of Intensive Care and Emergency Medicine, vol 2005. Springer, New York, NY. https://doi.org/10.1007/0-387-26272-5_30

Download citation

  • DOI: https://doi.org/10.1007/0-387-26272-5_30

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-3-540-23476-0

  • Online ISBN: 978-0-387-26272-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation